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The recommended phase II dose of paclitaxel 180mgm
 2 given as a 3-h infusion followed by nedaplatin 100mgm
 2 in a 1-h infusion
every 3–4 weeks was determined in 52 chemo-naive patients with unresectable squamous cell carcinoma (SCC), with a promising
response rate for lung SCC of 55%.
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Squamous cell carcinoma (SCC) arises from the epithelial tissue of
many different organs. Although localised diseases can be treated
using surgical resection or curative radiotherapy, advanced SCC
continues to have a poor prognosis and the standard treatment has
not been established (DeVita et al, 2001). Cisplatin-based
chemotherapy has been used for the treatment of advanced SCC,
regardless of the site of tumour origin (DeVita et al, 2001).
Nedaplatin (cis-diammine-glycolate-O,O0-platinum II, 254-S) is
a second-generation platinum derivative that has an antitumour
activity comparable to that of cisplatin (Kobayashi et al, 1991) but
is less toxic to the kidney (Kameyama et al, 1990), as seen in
preclinical experiments. Nedaplatin produced promising response
rates in phase II trials for the treatment of SCC arising from the
head and neck (Inuyama et al, 1992), lung (Yamamoto et al, 2000),
oesophagus (Taguchi et al, 1992), and uterine cervix (Noda et al,
1992). Paclitaxel is another promising drug for the treatment of
advanced SCC, as shown by the favourable response rates obtained
in phase II trials for head and neck (Forastiere et al, 1998), non-
small-cell lung (Sekine et al, 1996), oesophageal (Ajani et al, 1994),
and cervical (McGuire et al, 1996) cancers.
A combination of nedaplatin and paclitaxel is a promising
chemotherapeutic regimen because a significant synergistic effect
was obtained for this combination in a preclinical mice tumour
model (Yamada et al, 2001), and the combination of platinum
compounds and paclitaxel is one of many standard regimens
(Schiller et al, 2002). The objectives of this phase I trial were (1) to
evaluate the toxicity of the regimen and to determine the maximum
tolerated dose (MTD) and recommended phase II dose (RPTD) of
nedaplatin and paclitaxel, and (2) to observe the antitumour effects
of this regimen on SCC arising in various organs.
PATIENTS AND METHODS
Patient selection
The eligibility criteria for enrolment in the trial were as follows:
histologically or cytologically proven SCC; unresectable disease;
measurable disease; no previous chemotherapy; age between 20
and 75 years; performance status of 0 or 1 (Oken et al, 1982);
adequate bone marrow function (white blood cell (WBC) count
X4.0 10
9l
 1, neutrophil count X2.0 10
9l
 1, haemoglobin
X10.0gdl
 1 and platelet count X100 10
9l
 1), liver function
(total bilirubin p1.5mgdl
 1 and transaminase p100IUl
 1), and
renal function (serum creatinine p1.5mgdl
 1 and creatinine
clearance X60mlmin
 1); and a PaO2 X60Torr. Patients were
excluded from the trial for any of the following reasons:
uncontrolled malignant pleural or pericardial effusion; a con-
comitant serious illness contraindicating chemotherapy; preg-
nancy; or breast-feeding. All patients gave their written informed
consent.
Treatment schedule
The levels and respective doses of paclitaxel (mgm
 2) and
nedaplatin (mgm
 2) are shown in Table 1. Paclitaxel diluted in
500ml of 5% glucose was administered as a 3-h intravenous
infusion with premedication as previously described (Sekine et al,
1996). Normal saline (500ml) and granisetron (40mgkg
 1)i n
100ml of normal saline were given intravenously, followed by
nedaplatin diluted in 250ml of normal saline administered in a 1-h
intravenous infusion. This treatment was repeated every 3–4
weeks.
Toxicity assessment and treatment modification
Complete blood cell counts and differential counts, routine
chemistry determinations, and a chest X-ray were performed
at least once a week throughout the course of treatment. If
grade 4 neutropenia was noted, the neutrophil count was repeated
4 days later to determine whether the grade 4 neutropenia
had lasted for 5 days or longer. Acute toxicity was
graded according to the NCI Common Toxicity Criteria, version
2.0, issued in 1998 (JCOG, 1998). Subsequent cycles of chemother-
apy were delayed if any of the following toxicities were noted
on day 1: WBC count p3.0 10
9l
 1, neutrophil count
p1.5 10
9l
 1, platelet count p100 10
9l
 1, serum creatinine
level X1.6mgdl
 1, grade 2 elevated hepatic transaminase level or
total serum bilirubin, fever X381C, or a performance status X2.
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lThe treatment was terminated if the above-mentioned toxicity
did not disappear in 3 weeks. If grade 4 leukopenia,
grade 4 neutropenia for 5 days or longer, grade 3–4 febrile
neutropenia, or grade 3–4 neutropenia with infection was
noted, 50mgm
 2 of granulocyte colony-stimulating factor
(G-CSF) was given subcutaneously, and the doses of paclitaxel
and nedaplatin were reduced by 25% in subsequent chemotherapy
cycles.
Dose-limiting toxicity, MTD, and RPTD
The dose-limiting toxicity (DLT) was defined as grade
4 neutropenia lasting 5 days or longer, grade 3–4 febrile
neutropenia, grade 3–4 neutropenia with infection, grade 4
leukopenia, a platelet count o20 10
9l
 1, and grade 3 or greater
nonhaematological toxicity other than nausea and vomiting.
Doses were escalated according to the frequency of DLT evaluated
during the first cycle of chemotherapy. Three patients
were initially enrolled at each dose level. If none of the patients
experienced DLT, the next cohort of patients was treated
at the next higher dose level. If one of the three patients
experienced DLT, then three additional patients were enrolled
at the same dose level, bringing the total to six patients for
that dose level. If two or fewer patients experienced DLT, the
next cohort of patients was treated at the next higher dose level.
If three or more of the six patients experienced DLT, that level
was considered to be the MTD. If two or all the initial
three patients experienced DLT, that level was considered
to be the MTD. The recommended dose for phase II trials was
defined as the dose preceding the MTD. Six to 15 additional
patients were enrolled at the RPTD to confirm that the frequency
of DLT was less than one-third.
Response evaluation
The objective tumour response was evaluated according to the
WHO criteria issued in 1979 (WHO, 1979).
Study design, data management, and statistical
considerations
The protocol and consent form were approved by the Institutional
Review Board of the National Cancer Center, Tokyo Japan. Data
management, periodic monitoring, and the final analysis were
performed by the Study Coordinator. A patient accrual period of
24 months and a follow-up period of 12 months were planned. The
overall survival time was estimated using the Kaplan–Meier
method (Armitage and Berry, 1994). Survival time was measured
from the date of study registration until the date of death from any
cause.
RESULTS
Patient characteristics
Between August 1999 and December 2002, 53 patients were
registered in the study. One patient at level 5 developed a bone
fracture prior to treatment and did not receive chemotherapy. This
patient was excluded from all the analyses. Of the remaining 52
patients (42 males and 10 females) with a median age of 62 years
(range 49–75), 42 (81%) patients had lung SCC, followed by
thymic SCC in five patients and head and neck SCC in four
patients. Of the 52 patients, 24 and 24 had metastatic and locally
advanced diseases, respectively.
Treatment delivery, toxicity, MTD, and RPTD
Treatment delivery was summarised in Table 2. Severe toxicity was
mainly manifested as leucopenia, neutropenia, and associated
infection, but the frequency of these symptoms did not differ
between dose levels (Table 3). Grade 3 anaemia and thrombocy-
topenia were only noted in one patient (5%) each; both these
patients had been treated at dose level 6. No grade 3–4 nausea,
neuropathy, or myalgia was noted. A grade 3–4 elevation in
creatinine, grade 3–4 hyponatremia, appetite loss, and diarrhoea
were only observed at level 6. One patient treated at level 6
Table 1 Dose level and number of patients accrued
No. of patients
Level
Paclitaxel
(mgm
 2)
Nedaplatin
(mgm
 2) Accrued
Evaluable for
DLT
a
Developing
DLT
a
1 135 60 6 6 2
2 150 60 3 3 0
3 150 80 3 3 0
4 180 80 7 6 1
5 180 100 12 12 4
6 210 100 21 19 8
aDose-limiting toxicity.
Table 2 Treatment delivery
No. of patients (%)
Levels 1–4
(n¼19)
Level 5
(n¼12)
Level 6
(n¼21)
Chemotherapy cycles
5 1 (5) 0 (0) 0 (0)
4 7 (37) 4 (33) 5 (24)
3 2 (11) 2 (17) 3 (14)
2 5 (26) 4 (33) 8 (38)
1 4 (21) 2 (17) 5 (24)
Median 3 3 2
Dose reduction in subsequent cycles
None 12 (63) 9 (75) 12 (50)
Required 3 (16) 1 (8) 4 (19)
Not administered 4 (21) 2 (17) 5 (24)
Table 3 Toxicity in all courses
Levels 1–4 (n¼19) Level 5 (n¼12) Level 6 (n¼21)
3 4 3–4 (%) 3 4 3–4 (%) 3 4 3–4 (%)
Leukopenia 6 0 (32) 5 0 (42) 6 1 (33)
Neutropenia 3 10 (68) 2 9 (92) 3 12 (71)
Anaemia 0 0 (0) 0 0 (0) 1 0 (5)
Thrombocytopenia 0 0 (0) 0 0 (0) 1 0 (5)
AST 0 0 (0) 0 0 (0) 1 0 (5)
ALT 0 0 (0) 1 0 (8) 0 1 (5)
Creatinine 0 0 (0) 0 0 (0) 0 1 (5)
Hyponatremia 0 0 (0) 0 0 (0) 2 1 (14)
Infection 4 0 (21) 4 0 (33) 6 0 (29)
Appetite loss 0 0 (0) 0 0 (0) 1 0 (5)
Diarrhoea 0 0 (0) 0 0 (0) 2 0 (10)
Constipation 0 0 (0) 0 0 (0) 0 1 (5)
Arrhythmia 2 0 (11) 0 0 (0) 0 0 (0)
Lung toxicity 0 0 (0) 0 0 (0) 2 0 (10)
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ldeveloped grade 2 leukopenia, fever, watery diarrhoea, and grade 4
ileus, but recovered in 5 days. Two patients at level 6 developed
grade 3 interstitial pneumonitis, but quickly recovered with oxygen
therapy alone in one patient and with oxygen and steroid therapy
in the other patient. No treatment-related deaths occurred in the
study.
In all, 19 DLTs were noted in 15 patients. Of the 1nine DLTs, 13
were neutropenic fever or documented infection and six were
nonhaematological. At level 6, only two of the first six patients
developed DLT; therefore, 15 additional patients were entered at
this level to confirm the frequency of DLT. Two patients were
excluded from the DLT analysis because G-CSF was administered
before the duration of grade 4 neutropenia had been determined
(protocol violation). Of the remaining 13 patients, six developed
DLT. Thus, eight (42%) of the 19 patients evaluated for DLT
developed DLT at level 6; this dose level was therefore determined
to be the MTD. An additional six patients were registered at level 5,
and four (33%) of the 12 patients at level 5 developed DLT; this
level was determined to be the RPTD.
Objective responses and survival
Of the 42 patients with lung SCC, two CRs and 21 PRs were noted,
and the overall response rate (95% confidence interval) was 55%
(39–70%). No difference in the response rates for levels 1–4 and
levels 5–6 were observed. One PR was noted in a patient with
thymic SCC, and one PR was noted in a patient with head and neck
SCC. The overall survival time (95% confidence interval) in all
patients (n¼52) was 11.1 (6.4–15.8) months.
DISCUSSION
This study showed that the combination of nedaplatin and
paclitaxel was feasible with acceptable toxicity, and that the RPTD
of nedaplatin was 100mgm
 2 over 1 hour, which is the full dose of
this agent, while that of paclitaxel was 180mgm
 2 over 3h. These
doses are comparable to doses for practical use and those
determined by previous phase I trials of cisplatin or carboplatin
in combination with paclitaxel, where 180–225mgm
 2 of
paclitaxel was given with the full dose of platinum-agent (Akiyama
et al, 2001; Kurata et al, 2001). The toxicity profile in the present
study was similar to that of the carboplatin and paclitaxel
combination (Akiyama et al, 2001).
The primary objectives of phase I trials are to evaluate toxicity
and to establish a recommended drug dose for a given adminis-
tration schedule; an additional goal of these trials is to look for
evidence of the drug’s antitumour activity. Objective tumour
responses to newly investigated drugs are a promising clue for
determining specific tumour types for subsequent phase II trials;
therefore, patients with various tumours are usually registered in
phase I trials (Sekine et al, 2002). In cases where some information
on the antitumour activity of a drug is available, patients can be
selected so that the chance of a response is maximised. This study
was a histology-oriented phase I trial, and objective tumour
responses were observed in about half of the patients.
The combination of nedaplatin and paclitaxel is particularly
promising for the treatment of patients with lung SCC, as shown by
the high response rate of 55%. Adenocarcinoma, large-cell
carcinoma, adenosquamous carcinoma, and SCC of the lung have
been grouped together as non-small-cell lung cancer because
treatment response and prognosis are similar for these histologies.
A recent cDNA microarray analysis of non-small-cell lung cancer
tissue, however, showed that the gene expression profiles of SCC
and adenocarcinoma are different (Kikuchi et al, 2003), and these
differences may lead to different responses to anticancer agents,
including nedaplatin. Thus, optimal chemotherapy regimens for
the treatment of non-small-cell lung cancer should be established
according to each tumour’s histology. The numbers of patients
with head and neck SCC and patients with thymic SCC were too
small to comment on the antitumour effects of this regimen.
In conclusion, the combination of nedaplatin and paclitaxel is a
feasible treatment, and the RPTD is paclitaxel 180mgm
 2 given as
a 3-h infusion followed by nedaplatin 100mgm
 2 in a 1-h infusion
every 3–4 weeks. This regimen was highly effective for the
treatment of untreated lung SCC.
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